Aller au contenu principal
Accès ouvert déclaré 2025 article

Impact of Biologics Initiation on Oral Corticosteroid Use in the International Severe Asthma Registry and the Optimum Patient Care Research Database: A Pooled Analysis of Real-World Data

15Citations signalées, ce qui n’est pas une note de qualité
104Institutions déclarées
29Pays d’affiliation déclarés

Rattachement africain : sg, it, us, bg, tw, ee, au, es, ar, gr, gb, se, be, nl, br, ca, co, dk, fr, ie, jp, kw, mx, no, pl, pt, sa, kr, ae. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: For severe asthma (SA) management, real-world evidence on the effects of biologic therapies in reducing the burden of oral corticosteroid (OCS) use is limited. OBJECTIVE: To estimate the efficacy of biologic initiation on total OCS (TOCS) exposure in patients with SA from real-world specialist and primary care settings. METHODS: From the International Severe Asthma Registry (ISAR, specialist care) and the Optimum Patient Care Research Database (OPCRD, primary care, United Kingdom), adult biologic initiators were identified and propensity score-matched with non-initiators (ISAR, 1:1; OPCRD, 1:2). The impact of biologic initiation on TOCS (including bursts for exacerbations) daily dose in the first- and second-year follow-up period was estimated using multivariable generalized linear models. RESULTS: Among 5,663 patients (ISAR 48%, OPCRD 52%), the odds ratios (ORs) of biologic initiators achieving TOCS cessation in the first and second years of follow-up were 2.38 (95% CI, 1.87-3.04) and 2.11 (95% CI, 1.65-2.70), whereas the ORs of low (0- to 5-mg) TOCS intake were 1.62 (95% CI, 1.40-1.86) and 1.40 (95% CI, 1.21-1.61), respectively. Compared with non-initiators, biologic initiators had a substantially higher chance of achieving greater than 75% reduction from baseline (OR [95% CI] = 2.35 [2.06-2.68] and 1.53 [1.35-1.73] in first and second years, respectively). These findings remained persistent and robust when analyses were repeated with one country setting removed at a time. CONCLUSIONS: Biologic initiation in patients with SA led to substantial reduction in TOCS exposure, particularly in the first year. Future analyses will explore the impact on OCS-related adverse health events.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Impact of Biologics Initiation on Oral Corticosteroid Use in the International Severe Asthma Registry and the Optimum Patient Care Research Database: A Pooled Analysis of Real-World Data
Date Crossref
01/08/2025
Éditeur
Elsevier BV
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

National University of SingaporeNational University Health SystemAstraZeneca (Italy)AstraZeneca (United States)Observational & Pragmatic Research InstituteMedical University of SofiaKaohsiung Medical UniversityTartu University HospitalUniversity of TartuCamden and Campbelltown HospitalsHealth Research Institute of the Balearic IslandsHospital Ramos MejíaNational and Kapodistrian University of AthensLaiko General Hospital of AthensUniversity General Hospital AttikonNational University of RosarioHospital Universitario AustralFavaloro FoundationHospital Donación Francisco SantojanniNational University of TucumánCentro Científico Tecnológico - TucumánAsociación por los Derechos CivilesAsociación Psicoanalítica de Buenos AiresENT and AllergyAstraZeneca (United Kingdom)University of IoanninaRoyal Brompton HospitalAstraZeneca (Sweden)Woolcock Institute of Medical ResearchMacquarie UniversityMonash HealthMonash UniversityJohn Hunter HospitalHunter Medical Research InstituteAlfred HealthUNSW SydneyThe George Institute for Global HealthWestmead HospitalThe University of QueenslandGhent University HospitalErasmus MCUniversity of LiègeSanta Casa HospitalUniversity Hospital St. Ivan RilskiVancouver Hospital and Health Sciences CentreVancouver General HospitalUniversity of AlbertaUniversity of TorontoUniversité LavalUniversité de SherbrookeUniversity of British ColumbiaQueen's UniversityPontificia Universidad JaverianaUniversidad de La SabanaFundación Neumológica ColombianaInstituto del Corazón de BucaramangaFrederiksberg HospitalBispebjerg HospitalCopenhagen University HospitalCentre National de la Recherche ScientifiqueInsermUniversité de MontpellierPhysiologie et Médecine Expérimentale du Coeur et des MusclesUniversity Hospital of IoanninaAthens State UniversityBeaumont HospitalTrinity College DublinHumanitas UniversityIRCCS Humanitas Research HospitalKindai University HospitalKobe UniversityKuwait UniversityMinistry of HealthHospital Médica SurHaukeland University HospitalMedical University of LodzCentro Hospitalar de Vila Nova de GaiaUniversidade do PortoCentre for Health Technology and Services ResearchHospitais da Universidade de CoimbraUniversity of CoimbraAlfaisal UniversityKing Fahd Medical CityUmm al-Qura UniversitySingapore General HospitalNational University HospitalThe Catholic University of Korea Seoul St. Mary's HospitalCatholic University of KoreaUniversidade de Santiago de CompostelaTaichung Veterans General HospitalTaipei Veterans General HospitalNational Taiwan UniversityNational Taiwan University HospitalRashid HospitalUniversity of SharjahDubai HospitalQueen's University BelfastKing's College LondonQueen Mary University of LondonBarts Health NHS TrustNational Jewish HealthUniversity of Colorado DenverUniversity of MichiganUniversity of North Carolina at Chapel Hill

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Asthma and respiratory diseasesDelphi Technique in ResearchDermatology and Skin Diseases

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.